Compounds > tenofovir
Page last updated: 2024-08-24

tenofovir and Delayed Effects, Prenatal Exposure

tenofovir has been researched along with Delayed Effects, Prenatal Exposure in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's3 (42.86)24.3611
2020's2 (28.57)2.80

Authors

AuthorsStudies
Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L1
Acosta, S; Balogun, K; Guzman Lenis, MS; Mount, HT; Sarkar, A; Serghides, L1
Bunders, MJ; Cohen, S; Denneman, L; Godfried, MH; Kuijpers, TW; Nellen, JF; Pajkrt, D; Scherpbier, HJ; Smit, C; van de Plas, A; van Leeuwen, E; Weijsenfeld, AM1
Ananworanich, J; Aurpibul, L; Bunupuradah, T; Kosalaraksa, P; Kurniati, N; Puthanakit, T; Sophonphan, J; Sudjaritruk, T1
Abrams, EJ; Brittain, K; Jao, J; M le Roux, S; Myer, L; Olatunbosun, S; Phillips, TK; Ronan, A; Zerbe, A1
Amani-Bosse, C; Arrivé, E; Blanche, S; Dabis, F; Ekouévi, DK; Gray, G; Hirt, D; Kone, M; Leang, SK; McIntyre, J; Nerrienet, E; Rey, E; Tréluyer, JM; Urien, S1
Arrivé, E; Avit, D; Blanche, S; Coffié, P; Dabis, F; Ekouévi, DK; Hirt, D; Lalsab, S; Leang, SK; McIntyre, J; Nerrienet, E; Rey, E; Tréluyer, JM; Urien, S1

Trials

1 trial(s) available for tenofovir and Delayed Effects, Prenatal Exposure

ArticleYear
Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).
    Clinical pharmacology and therapeutics, 2009, Volume: 85, Issue:2

    Topics: Adenine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Maternal-Fetal Exchange; Organophosphonates; Population Groups; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Tenofovir

2009

Other Studies

6 other study(ies) available for tenofovir and Delayed Effects, Prenatal Exposure

ArticleYear
Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.
    Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:8

    Topics: Abnormalities, Drug-Induced; Adenine; Adult; Alanine; Chemoprevention; China; Cohort Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infectious Disease Transmission, Vertical; Male; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load

2020
In utero exposure to protease inhibitor-based antiretroviral regimens delays growth and developmental milestones in mice.
    PloS one, 2020, Volume: 15, Issue:11

    Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Developmental Disabilities; Dideoxynucleosides; Emtricitabine; Exploratory Behavior; Female; Fetal Growth Retardation; Growth Disorders; Hand Strength; HIV Protease Inhibitors; Homing Behavior; Lamivudine; Male; Mice; Mice, Inbred C57BL; Pregnancy; Prenatal Exposure Delayed Effects; Random Allocation; Reflex, Abnormal; Reflex, Righting; Sensation Disorders; Taxis Response; Tenofovir

2020
In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy/HIV-exposed infants.
    AIDS (London, England), 2016, 08-24, Volume: 30, Issue:13

    Topics: Anti-HIV Agents; Birth Weight; Child Development; Female; Fetal Development; Fetal Growth Retardation; Follow-Up Studies; Growth Disorders; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Retrospective Studies; Tenofovir

2016
Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents.
    Antiviral therapy, 2017, Volume: 22, Issue:6

    Topics: Adolescent; Antiretroviral Therapy, Highly Active; Biomarkers; Bone and Bones; Bone Density; CD4 Lymphocyte Count; Child; Cross-Sectional Studies; Female; HIV Infections; Humans; Kidney Function Tests; Male; Pregnancy; Prenatal Exposure Delayed Effects; Severity of Illness Index; Tenofovir

2017
Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants.
    AIDS (London, England), 2017, Jan-02, Volume: 31, Issue:1

    Topics: Adult; Anthropometry; Anti-HIV Agents; Body Height; Child Development; Female; HIV Infections; Humans; Infant; Infant, Newborn; Male; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Prospective Studies; South Africa; Tenofovir; Young Adult

2017
Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3

    Topics: Adenine; Anti-HIV Agents; Area Under Curve; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; Half-Life; HIV Infections; HIV-1; Humans; Infant, Newborn; Maternal-Fetal Exchange; Organophosphonates; Population Groups; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Tenofovir

2009